2 | Multicenter study evaluating target attainment of anti-Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients. (Chanas T, Gibson G, Langenstroer E, Herrmann DJ, Carver TW, Alexander K, Chui SHJ, Rein L, Ha M, Maynard KM, Bamberg K, O'Keefe M, O'Brien M, Gonzalez MC, Hobbs B, Pajoumand M, Peppard WJ) Pharmacotherapy 2024 Mar;44(3):258-267 |
3 | Evaluation of a novel blood volume-based enoxaparin dosing guideline for venous thromboembolism prophylaxis in trauma patients. (Langenstroer EA, Carver TW, Herrmann DJ, O'Keefe MM, Hubbard S, Holschbach L, Rein L, Peppard WJ) Am J Health Syst Pharm 2023 Aug 18;80(17):1137-1146 1 Citation |
1 | The efficacy of various Enoxaparin dosing regimens in general surgery patients: A systematic review. (Al Tannir AH, Biesboer EA, Pokrzywa CJ, Figueroa J, Harding E, de Moya MA, Morris RS, Murphy PB) Surgery 2023 Aug;174(2):315-323 |
3 | Evaluation of an Association Between Enoxaparin Dose per Estimated Blood Volume and Clinically Relevant Bleeding in Low-Weight Trauma Patients. (Carter C, Denny K, Carver TW, Jung B, Rein L, Peppard WJ) Ann Pharmacother 2024 Feb;58(2):118-125 1 Citation |
1 | Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Emergency General Surgery Patients. (Pokrzywa CJ, Biesboer EA, Figueroa J, Al Tannir AH, de Moya M, Morris RS, Murphy PB) J Am Coll Surg 2023 Aug 01;237(2):195-203 |
3 | Effectiveness of Body Mass Index-Based Prophylactic Enoxaparin Dosing in Bariatric Surgery Patients. (Chang CK, Higgins RM, Rein L, Peppard WJ, Herrmann DJ, Kindel T) J Surg Res 2023 Jul;287:168-175 4 Citations |
2 | Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients. (Scheuermann A, Liegl M, Simpson P, Branchford B, Malec L) J Pediatr Hematol Oncol 2023 Jan 01;45(1):e65-e69 1 Citation |
1 | Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. (Sochet AA, Morrison JM, Jaffray J, Godiwala N, Wilson HP, Thornburg CD, Bhat RV, Zia A, Lawrence C, Kudchadkar SR, Hamblin F, Russell CJ, Streiff MB, Spyropoulos AC, Amankwah EK, Goldenberg NA, COVID-19 Anticoagulation in Children – Thromboprophylaxis (COVAC-TP) Trial Investigators) Pediatrics 2022 Jul 01;150(1) 18 Citations |
3 | Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients. (O'Keefe MM, Carver TW, Herrmann DJ, Prom A, Hubbard S, Rein LE, Peppard WJ) Pharmacotherapy 2022 Mar;42(3):216-223 6 Citations |
1 | Anti-Xa based dosing of enoxaparin in hematopoietic stem cell transplant and adoptive cell therapy patients: A single center experience. (Jizzini M, Akhtar OS, Atwood K, Ji W, Pleskow J, Bat T, Balderman S) Thromb Res 2022 Mar;211:6-9 |
2 | A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal. (Baumann Kreuziger L, Feng M, Bartosic A, Simpson P, Wang TF) Blood Coagul Fibrinolysis 2022 Apr 01;33(3):171-175 4 Citations |
1 | Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. (Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI, HEP-COVID Investigators) JAMA Intern Med 2021 Dec 01;181(12):1612-1620 293 Citations |
1 | Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. (Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC) Thromb Haemost 2021 Dec;121(12):1684-1695 9 Citations |
1 | Portal Vein Thrombosis After Total Pancreatectomy and Islet Autotransplant: Prophylaxis and Graft Impact. (Robbins AJ, Skube ME, Bellin MD, Dunn TB, Chapman SA, Berry KL, Lusczek E, Beilman GJ) Pancreas 2019;48(10):1329-1333 14 Citations |
1 | Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. (Cohoon KP, De Sanctis Y, Haskell L, McBane RD, Spiro TE) J Thromb Haemost 2018 Jul;16(7):1278-1287 22 Citations |
1 | A Rare Complication of Campylobacter Sepsis in an Infant. (Kaenkumchorn T, Kesavan A) Clin Pediatr (Phila) 2018 Apr;57(4):484-487 2 Citations |
1 | Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. (Wood JP, Baumann Kreuziger LM, Desai UR, Mast AE) Br J Haematol 2016 Oct;175(1):123-32 3 Citations |
1 | Enoxaparin ameliorates post-traumatic brain injury edema and neurologic recovery, reducing cerebral leukocyte endothelial interactions and vessel permeability in vivo. (Li S, Marks JA, Eisenstadt R, Kumasaka K, Samadi D, Johnson VE, Holena DN, Allen SR, Browne KD, Smith DH, Pascual JL) J Trauma Acute Care Surg 2015 Jul;79(1):78-84 38 Citations |
3 | Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*. (Schloemer NJ, Abu-Sultaneh S, Hanson SJ, Yan K, Hoffmann RG, Punzalan RC, Havens PL) Pediatr Crit Care Med 2014 Sep;15(7):e294-9 19 Citations |
1 | Retrograde migration and endovascular retrieval of a venous bullet embolus. (Schroeder ME, Pryor HI 2nd, Chun AK, Rahbar R, Arora S, Vaziri K) J Vasc Surg 2011 Apr;53(4):1113-5 31 Citations |
2 | Low-molecular-weight heparin in thrombotic disease in children and adolescents. (Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC) J Pediatr Hematol Oncol 2000;22(2):137-42 74 Citations |